title: Liraglutide as additional treatment for type 1 diabetes.
abstract: OBJECTIVE
  To determine whether the addition of liraglutide to insulin to treat patients with type 1 diabetes leads to an improvement in glycemic control and diminish glycemic variability.
  
  
  METHODS
  In this study, 14 patients with well-controlled type 1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for 1 week. Of the 14 patients, eight continued therapy for 24 weeks.
  
  
  RESULTS
  In all the 14 patients, mean fasting and mean weekly glucose concentrations significantly decreased after 1 week from 130±10 to 110±8  mg/dl (P<0.01) and from 137.5±20 to 115±12  mg/dl (P<0.01) respectively. Glycemic excursions significantly improved at 1 week. The mean s.d. of glucose concentrations decreased from 56±10 to 26±6  mg/dl (P<0.01) and the coefficient of variation decreased from 39.6±10 to 22.6±7 (P<0.01). There was a concomitant fall in the basal insulin from 24.5±6 to 16.5±6 units (P<0.01) and bolus insulin from 22.5±4 to 15.5±4 units (P<0.01). In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, and basal and bolus insulin dose also significantly decreased (P<0.01). HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (P=0.02), as did the body weight by 4.5±1.5  kg (P=0.02).
  
  
  CONCLUSIONS
  Liraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, New York 14209, USA.
authors.forename: Ajay
authors.initials: A
authors.lastname: Varanasi
authors.forename: Natalie
authors.initials: N
authors.lastname: Bellini
authors.forename: Deepti
authors.initials: D
authors.lastname: Rawal
authors.forename: Mehul
authors.initials: M
authors.lastname: Vora
authors.forename: Antoine
authors.initials: A
authors.lastname: Makdissi
authors.forename: Sandeep
authors.initials: S
authors.lastname: Dhindsa
authors.forename: Ajay
authors.initials: A
authors.lastname: Chaudhuri
authors.forename: Paresh
authors.initials: P
authors.lastname: Dandona
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage; D000069450:Liraglutide; D008297:Male; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069450:Liraglutide